顶部logo
顶部logo
more_1

home

ホーム > レポート一覧 > β-ラクタム系及びβ-ラクタマーゼ阻害剤の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2025～2031年）

β-ラクタム系及びβ-ラクタマーゼ阻害剤の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2025～2031年）

Beta-lactam and Beta-lactamase Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
  • レポートID：
    13646
  • 発表時期：
    2025-02-06
  • レポート形式：
    PDF
  • 産業カテゴリー：
    薬品及びサプリメント
  • レポート言語：
    英語、日本語
  • ページ数：
    141
  • 発行会社（調査会社）：
    QYResearch
title

言語とエディションの価格

  • 英語版
  • 日本語版
  • 英語と日本語版

個人版詳細

マルチユーザー版詳細

企業版詳細

  • 英語版
  • 日本語版
  • 英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.40円。

※米ドル表示価格+10％消費税。

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

title

レポートの概要

本報告書は、世界のβ-ラクタム系及びβ-ラクタマーゼ阻害剤市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点からβ-ラクタム系及びβ-ラクタマーゼ阻害剤市場を分析し、需要構造と成長特性を明確化します。
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、β-ラクタム系及びβ-ラクタマーゼ阻害剤に関する的確な意思決定を行うための実践的なインサイトを提供します。
 主要β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の統計
2025年世界市場規模：28210百万米ドル
2026年世界市場規模：28710百万米ドル
2032年予測市場規模：32210百万米ドル
2026–2032年予測期間CAGR：1.9%
本レポートはβ-ラクタム系及びβ-ラクタマーゼ阻害剤市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の主要企業には以下が含まれます：
Pfizer
Novartis (Sandoz)
TEVA
Merck & Co.
AbbVie (Allergan)
Sumitomo Dainippon
Hikma
Aurobindo Pharma
Wockhardt
Lupin Limited
Fresenius Kabi
B. Braun
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
Nichi-Iko (Sagent)
Antibiotice 

製品別
Penicillins
Cephalosporins
Carbapenems
Monobactams
Combinations 

アプリケーション別
Oral
Intravenous 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他

レポート構成（章別概要）
第1章｜市場概要と成長展望
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別にβ-ラクタム系及びβ-ラクタマーゼ阻害剤市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別にβ-ラクタム系及びβ-ラクタマーゼ阻害剤市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
●β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の全体像と成長見通し
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境がβ-ラクタム系及びβ-ラクタマーゼ阻害剤市場に与える影響を分析いたします。
●市場環境の構成要素とマクロトレンド
β-ラクタム系及びβ-ラクタマーゼ阻害剤産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します。
●競争構造と主要企業の動向分析
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します。
●競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点からβ-ラクタム系及びβ-ラクタマーゼ阻害剤市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします。
●成長要因・課題・リスクの分析
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します。
●将来トレンドと市場展望
β-ラクタム系及びβ-ラクタマーゼ阻害剤市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします。
title

Description

The global market for Beta-lactam and Beta-lactamase Inhibitors was estimated to be worth US$ 28210 million in 2024 and is forecast to a readjusted size of US$ 32210 million by 2031 with a CAGR of 1.9% during the forecast period 2025-2031.

β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.
Global key players of beta-lactam and beta-lactamase Inhibitors include Pfizer, USantibiotics, TEVA, Novartis (Sandoz), Antibiotice. Global top five manufacturers hold a share over 10%. Asia-Pacific is the largest market of beta-lactam and beta-lactamase Inhibitors, holds a share over 30%, followed by Europe, and North America, with a share of 30% and 20% respectively. In terms of product, cephalosporins is the largest segment, with a share over 38%. And in terms of application, the largest application is in Intravenous with a share about 50%.

This report aims to provide a comprehensive presentation of the global market for Beta-lactam and Beta-lactamase Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Beta-lactam and Beta-lactamase Inhibitors by region & country, by Type, and by Application.

The Beta-lactam and Beta-lactamase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Beta-lactam and Beta-lactamase Inhibitors.

Market Segmentation
By Company
    Pfizer
    Novartis (Sandoz)
    TEVA
    Merck & Co.
    AbbVie (Allergan)
    Sumitomo Dainippon
    Hikma
    Aurobindo Pharma
    Wockhardt
    Lupin Limited
    Fresenius Kabi
    B. Braun
    USantibiotics
    Qilu Pharmaceutical
    ACS Dobfar
    Nichi-Iko (Sagent)
    Antibiotice

Segment by Type
    Penicillins
    Cephalosporins
    Carbapenems
    Monobactams
    Combinations

Segment by Application
    Oral
    Intravenous

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia-Pacific
    Europe
        Germany
        France
        U.K.
        Italy
        Netherlands
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Beta-lactam and Beta-lactamase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Beta-lactam and Beta-lactamase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Beta-lactam and Beta-lactamase Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
title

Table of Contents

1 Market Overview
    1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction
    1.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Forecast
        1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value (2020-2031)
        1.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume (2020-2031)
        1.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Price (2020-2031)
    1.3 Beta-lactam and Beta-lactamase Inhibitors Market Trends & Drivers
        1.3.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends
        1.3.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers & Opportunity
        1.3.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges
        1.3.4 Beta-lactam and Beta-lactamase Inhibitors Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered
2 Competitive Analysis by Company
    2.1 Global Beta-lactam and Beta-lactamase Inhibitors Players Revenue Ranking (2024)
    2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Company (2020-2025)
    2.3 Global Beta-lactam and Beta-lactamase Inhibitors Players Sales Volume Ranking (2024)
    2.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Company Players (2020-2025)
    2.5 Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Company (2020-2025)
    2.6 Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base and Headquarters
    2.7 Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of Beta-lactam and Beta-lactamase Inhibitors
    2.9 Beta-lactam and Beta-lactamase Inhibitors Market Competitive Analysis
        2.9.1 Beta-lactam and Beta-lactamase Inhibitors Market Concentration Rate (2020-2025)
        2.9.2 Global 5 and 10 Largest Manufacturers by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2024
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Beta-lactam and Beta-lactamase Inhibitors as of 2024)
    2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Penicillins
        3.1.2 Cephalosporins
        3.1.3 Carbapenems
        3.1.4 Monobactams
        3.1.5 Combinations
    3.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type
        3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (2020 VS 2024 VS 2031)
        3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value, by Type (2020-2031)
        3.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value, by Type (%) (2020-2031)
    3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Type
        3.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031)
        3.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume, by Type (2020-2031)
        3.3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume, by Type (%) (2020-2031)
    3.4 Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Type (2020-2031)
4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Oral
        4.1.2 Intravenous
    4.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application
        4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (2020 VS 2024 VS 2031)
        4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value, by Application (2020-2031)
        4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value, by Application (%) (2020-2031)
    4.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Application
        4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031)
        4.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume, by Application (2020-2031)
        4.3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume, by Application (%) (2020-2031)
    4.4 Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Application (2020-2031)
5 Segmentation by Region
    5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region
        5.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031
        5.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (2020-2025)
        5.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (2026-2031)
        5.1.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (%), (2020-2031)
    5.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region
        5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region: 2020 VS 2024 VS 2031
        5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (2020-2025)
        5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (2026-2031)
        5.2.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (%), (2020-2031)
    5.3 Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Region (2020-2031)
    5.4 North America
        5.4.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        5.4.2 North America Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
    5.5 Europe
        5.5.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        5.5.2 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
    5.6 Asia Pacific
        5.6.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        5.6.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (%), 2024 VS 2031
    5.7 South America
        5.7.1 South America Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        5.7.2 South America Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        5.8.2 Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Value Growth Trends, 2020 VS 2024 VS 2031
    6.2 Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Value
        6.2.1 Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.2.2 Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Volume, 2020-2031
    6.3 United States
        6.3.1 United States Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.3.2 United States Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
        6.3.3 United States Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application, 2024 VS 2031
    6.4 Europe
        6.4.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.4.2 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
        6.4.3 Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application, 2024 VS 2031
    6.5 China
        6.5.1 China Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.5.2 China Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
        6.5.3 China Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application, 2024 VS 2031
    6.6 Japan
        6.6.1 Japan Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.6.2 Japan Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
        6.6.3 Japan Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application, 2024 VS 2031
    6.7 South Korea
        6.7.1 South Korea Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.7.2 South Korea Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
        6.7.3 South Korea Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application, 2024 VS 2031
    6.8 Southeast Asia
        6.8.1 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.8.2 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
        6.8.3 Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application, 2024 VS 2031
    6.9 India
        6.9.1 India Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020-2031
        6.9.2 India Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
        6.9.3 India Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application, 2024 VS 2031
7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Company Information
        7.1.2 Pfizer Introduction and Business Overview
        7.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.1.5 Pfizer Recent Development
    7.2 Novartis (Sandoz)
        7.2.1 Novartis (Sandoz) Company Information
        7.2.2 Novartis (Sandoz) Introduction and Business Overview
        7.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.2.5 Novartis (Sandoz) Recent Development
    7.3 TEVA
        7.3.1 TEVA Company Information
        7.3.2 TEVA Introduction and Business Overview
        7.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.3.5 TEVA Recent Development
    7.4 Merck & Co.
        7.4.1 Merck & Co. Company Information
        7.4.2 Merck & Co. Introduction and Business Overview
        7.4.3 Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.4.4 Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.4.5 Merck & Co. Recent Development
    7.5 AbbVie (Allergan)
        7.5.1 AbbVie (Allergan) Company Information
        7.5.2 AbbVie (Allergan) Introduction and Business Overview
        7.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.5.5 AbbVie (Allergan) Recent Development
    7.6 Sumitomo Dainippon
        7.6.1 Sumitomo Dainippon Company Information
        7.6.2 Sumitomo Dainippon Introduction and Business Overview
        7.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.6.5 Sumitomo Dainippon Recent Development
    7.7 Hikma
        7.7.1 Hikma Company Information
        7.7.2 Hikma Introduction and Business Overview
        7.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.7.5 Hikma Recent Development
    7.8 Aurobindo Pharma
        7.8.1 Aurobindo Pharma Company Information
        7.8.2 Aurobindo Pharma Introduction and Business Overview
        7.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.8.5 Aurobindo Pharma Recent Development
    7.9 Wockhardt
        7.9.1 Wockhardt Company Information
        7.9.2 Wockhardt Introduction and Business Overview
        7.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.9.5 Wockhardt Recent Development
    7.10 Lupin Limited
        7.10.1 Lupin Limited Company Information
        7.10.2 Lupin Limited Introduction and Business Overview
        7.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.10.5 Lupin Limited Recent Development
    7.11 Fresenius Kabi
        7.11.1 Fresenius Kabi Company Information
        7.11.2 Fresenius Kabi Introduction and Business Overview
        7.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.11.5 Fresenius Kabi Recent Development
    7.12 B. Braun
        7.12.1 B. Braun Company Information
        7.12.2 B. Braun Introduction and Business Overview
        7.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.12.5 B. Braun Recent Development
    7.13 USantibiotics
        7.13.1 USantibiotics Company Information
        7.13.2 USantibiotics Introduction and Business Overview
        7.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.13.5 USantibiotics Recent Development
    7.14 Qilu Pharmaceutical
        7.14.1 Qilu Pharmaceutical Company Information
        7.14.2 Qilu Pharmaceutical Introduction and Business Overview
        7.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.14.5 Qilu Pharmaceutical Recent Development
    7.15 ACS Dobfar
        7.15.1 ACS Dobfar Company Information
        7.15.2 ACS Dobfar Introduction and Business Overview
        7.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.15.5 ACS Dobfar Recent Development
    7.16 Nichi-Iko (Sagent)
        7.16.1 Nichi-Iko (Sagent) Company Information
        7.16.2 Nichi-Iko (Sagent) Introduction and Business Overview
        7.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.16.5 Nichi-Iko (Sagent) Recent Development
    7.17 Antibiotice
        7.17.1 Antibiotice Company Information
        7.17.2 Antibiotice Introduction and Business Overview
        7.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
        7.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Offerings
        7.17.5 Antibiotice Recent Development
8 Industry Chain Analysis
    8.1 Beta-lactam and Beta-lactamase Inhibitors Industrial Chain
    8.2 Beta-lactam and Beta-lactamase Inhibitors Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Beta-lactam and Beta-lactamase Inhibitors Sales Model
        8.5.2 Sales Channel
        8.5.3 Beta-lactam and Beta-lactamase Inhibitors Distributors
9 Research Findings and Conclusion
10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer
title

Table of Figures

List of Tables
 Table 1. Beta-lactam and Beta-lactamase Inhibitors Market Trends
 Table 2. Beta-lactam and Beta-lactamase Inhibitors Market Drivers & Opportunity
 Table 3. Beta-lactam and Beta-lactamase Inhibitors Market Challenges
 Table 4. Beta-lactam and Beta-lactamase Inhibitors Market Restraints
 Table 5. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Company (2020-2025)
 Table 7. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Company (2020-2025) & (M Units)
 Table 8. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume Market Share by Company (2020-2025)
 Table 9. Global Market Beta-lactam and Beta-lactamase Inhibitors Price by Company (2020-2025) & (US$/Unit)
 Table 10. Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Manufacturing Base and Headquarters
 Table 11. Key Manufacturers Beta-lactam and Beta-lactamase Inhibitors Product Type
 Table 12. Key Manufacturers Time to Begin Mass Production of Beta-lactam and Beta-lactamase Inhibitors
 Table 13. Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Beta-lactam and Beta-lactamase Inhibitors as of 2024)
 Table 15. Mergers & Acquisitions, Expansion Plans
 Table 16. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 17. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (2020-2025) & (US$ Million)
 Table 18. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (2026-2031) & (US$ Million)
 Table 19. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2020-2025)
 Table 20. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2026-2031)
 Table 21. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Type: 2020 VS 2024 VS 2031 (M Units)
 Table 22. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Type (2020-2025) & (M Units)
 Table 23. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Type (2026-2031) & (M Units)
 Table 24. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2020-2025)
 Table 25. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2026-2031)
 Table 26. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2020-2025) & (US$/Unit)
 Table 27. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2026-2031) & (US$/Unit)
 Table 28. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 29. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (2020-2025) & (US$ Million)
 Table 30. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (2026-2031) & (US$ Million)
 Table 31. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2020-2025)
 Table 32. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2026-2031)
 Table 33. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Application: 2020 VS 2024 VS 2031 (M Units)
 Table 34. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Application (2020-2025) & (M Units)
 Table 35. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Application (2026-2031) & (M Units)
 Table 36. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2020-2025)
 Table 37. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2026-2031)
 Table 38. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2020-2025) & (US$/Unit)
 Table 39. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2026-2031) & (US$/Unit)
 Table 40. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 41. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (2020-2025) & (US$ Million)
 Table 42. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (2026-2031) & (US$ Million)
 Table 43. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (2020-2025) & (%)
 Table 44. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (2026-2031) & (%)
 Table 45. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (M Units): 2020 VS 2024 VS 2031
 Table 46. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (2020-2025) & (M Units)
 Table 47. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (2026-2031) & (M Units)
 Table 48. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (2020-2025) & (%)
 Table 49. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Region (2026-2031) & (%)
 Table 50. Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Region (2020-2025) & (US$/Unit)
 Table 51. Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Region (2026-2031) & (US$/Unit)
 Table 52. Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 53. Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2025) & (US$ Million)
 Table 54. Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2026-2031) & (US$ Million)
 Table 55. Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Volume, (2020-2025) & (M Units)
 Table 56. Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Volume, (2026-2031) & (M Units)
 Table 57. Pfizer Company Information
 Table 58. Pfizer Introduction and Business Overview
 Table 59. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 60. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 61. Pfizer Recent Development
 Table 62. Novartis (Sandoz) Company Information
 Table 63. Novartis (Sandoz) Introduction and Business Overview
 Table 64. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 65. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 66. Novartis (Sandoz) Recent Development
 Table 67. TEVA Company Information
 Table 68. TEVA Introduction and Business Overview
 Table 69. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 70. TEVA Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 71. TEVA Recent Development
 Table 72. Merck & Co. Company Information
 Table 73. Merck & Co. Introduction and Business Overview
 Table 74. Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 75. Merck & Co. Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 76. Merck & Co. Recent Development
 Table 77. AbbVie (Allergan) Company Information
 Table 78. AbbVie (Allergan) Introduction and Business Overview
 Table 79. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 80. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 81. AbbVie (Allergan) Recent Development
 Table 82. Sumitomo Dainippon Company Information
 Table 83. Sumitomo Dainippon Introduction and Business Overview
 Table 84. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 85. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 86. Sumitomo Dainippon Recent Development
 Table 87. Hikma Company Information
 Table 88. Hikma Introduction and Business Overview
 Table 89. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Hikma Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 91. Hikma Recent Development
 Table 92. Aurobindo Pharma Company Information
 Table 93. Aurobindo Pharma Introduction and Business Overview
 Table 94. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 95. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 96. Aurobindo Pharma Recent Development
 Table 97. Wockhardt Company Information
 Table 98. Wockhardt Introduction and Business Overview
 Table 99. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 100. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 101. Wockhardt Recent Development
 Table 102. Lupin Limited Company Information
 Table 103. Lupin Limited Introduction and Business Overview
 Table 104. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 105. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 106. Lupin Limited Recent Development
 Table 107. Fresenius Kabi Company Information
 Table 108. Fresenius Kabi Introduction and Business Overview
 Table 109. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 110. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 111. Fresenius Kabi Recent Development
 Table 112. B. Braun Company Information
 Table 113. B. Braun Introduction and Business Overview
 Table 114. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 115. B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 116. B. Braun Recent Development
 Table 117. USantibiotics Company Information
 Table 118. USantibiotics Introduction and Business Overview
 Table 119. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 120. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 121. USantibiotics Recent Development
 Table 122. Qilu Pharmaceutical Company Information
 Table 123. Qilu Pharmaceutical Introduction and Business Overview
 Table 124. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 125. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 126. Qilu Pharmaceutical Recent Development
 Table 127. ACS Dobfar Company Information
 Table 128. ACS Dobfar Introduction and Business Overview
 Table 129. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 130. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 131. ACS Dobfar Recent Development
 Table 132. Nichi-Iko (Sagent) Company Information
 Table 133. Nichi-Iko (Sagent) Introduction and Business Overview
 Table 134. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 135. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 136. Nichi-Iko (Sagent) Recent Development
 Table 137. Antibiotice Company Information
 Table 138. Antibiotice Introduction and Business Overview
 Table 139. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 140. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Offerings
 Table 141. Antibiotice Recent Development
 Table 142. Key Raw Materials Lists
 Table 143. Raw Materials Key Suppliers Lists
 Table 144. Beta-lactam and Beta-lactamase Inhibitors Downstream Customers
 Table 145. Beta-lactam and Beta-lactamase Inhibitors Distributors List
 Table 146. Research Programs/Design for This Report
 Table 147. Key Data Information from Secondary Sources
 Table 148. Key Data Information from Primary Sources


List of Figures
 Figure 1. Beta-lactam and Beta-lactamase Inhibitors Product Picture
 Figure 2. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value (2020-2031) & (US$ Million)
 Figure 4. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume (2020-2031) & (M Units)
 Figure 5. Global Beta-lactam and Beta-lactamase Inhibitors Sales Price (2020-2031) & (US$/Unit)
 Figure 6. Beta-lactam and Beta-lactamase Inhibitors Report Years Considered
 Figure 7. Global Beta-lactam and Beta-lactamase Inhibitors Players Revenue Ranking (2024) & (US$ Million)
 Figure 8. Global Beta-lactam and Beta-lactamase Inhibitors Players Sales Volume Ranking (2024) & (M Units)
 Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2024
 Figure 10. Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 11. Penicillins Picture
 Figure 12. Cephalosporins Picture
 Figure 13. Carbapenems Picture
 Figure 14. Monobactams Picture
 Figure 15. Combinations Picture
 Figure 16. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 17. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value Market Share by Type, 2024 & 2031
 Figure 18. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031) & (M Units)
 Figure 19. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume Market Share by Type, 2024 & 2031
 Figure 20. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2020-2031) & (US$/Unit)
 Figure 21. Product Picture of Oral
 Figure 22. Product Picture of Intravenous
 Figure 23. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 24. Global Beta-lactam and Beta-lactamase Inhibitors Sales Value Market Share by Application, 2024 & 2031
 Figure 25. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031) & (M Units)
 Figure 26. Global Beta-lactam and Beta-lactamase Inhibitors Sales Volume Market Share by Application, 2024 & 2031
 Figure 27. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2020-2031) & (US$/Unit)
 Figure 28. North America Beta-lactam and Beta-lactamase Inhibitors Sales Value (2020-2031) & (US$ Million)
 Figure 29. North America Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
 Figure 30. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 31. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
 Figure 32. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Value by Region (%), 2024 VS 2031
 Figure 34. South America Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 35. South America Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
 Figure 36. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 37. Middle East & Africa Beta-lactam and Beta-lactamase Inhibitors Sales Value by Country (%), 2024 VS 2031
 Figure 38. Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Value (%), (2020-2031)
 Figure 39. Key Countries/Regions Beta-lactam and Beta-lactamase Inhibitors Sales Volume (%), (2020-2031)
 Figure 40. United States Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 41. United States Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
 Figure 42. United States Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (%), 2024 VS 2031
 Figure 43. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 44. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
 Figure 45. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (%), 2024 VS 2031
 Figure 46. China Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 47. China Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
 Figure 48. China Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (%), 2024 VS 2031
 Figure 49. Japan Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 50. Japan Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
 Figure 51. Japan Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (%), 2024 VS 2031
 Figure 52. South Korea Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 53. South Korea Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
 Figure 54. South Korea Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (%), 2024 VS 2031
 Figure 55. Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 56. Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
 Figure 57. Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (%), 2024 VS 2031
 Figure 58. India Beta-lactam and Beta-lactamase Inhibitors Sales Value, (2020-2031) & (US$ Million)
 Figure 59. India Beta-lactam and Beta-lactamase Inhibitors Sales Value by Type (%), 2024 VS 2031
 Figure 60. India Beta-lactam and Beta-lactamase Inhibitors Sales Value by Application (%), 2024 VS 2031
 Figure 61. Beta-lactam and Beta-lactamase Inhibitors Industrial Chain
 Figure 62. Beta-lactam and Beta-lactamase Inhibitors Manufacturing Cost Structure
 Figure 63. Channels of Distribution (Direct Sales, and Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット
  • jiantou

    多言語（英語、日本語）のサンプル提供

  • jiantou

    プロフェッショナルな日本語翻訳を提供

  • jiantou

    請求書、クレジットカードでのお支払いが可能です

  • jiantou

    必要なチャプターやカスタマイズされたレポートの注文が可能

  • jiantou

    購入後、アナリストに直接連絡することができます

購入方法
shunxu

  • 必要な言語とバージョンのレポート選択

  • レポート要件と見積もり依頼

  • 電子メールによる注文

  • レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）

  • クレジットカード決済、オフライン振込に対応（後払い可）

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）
ご利用ガイド
利用規約よくあるご質問プライバシーポリシー支払い方法と購入ガイド
お電話でのお問い合わせ
email050-5840-2692 日本
email0081-50-5840-2692 グローバル
9:00-18:00 (土日・祝日を除く)
底部logo
Copyright 2016-2026 Global Reports著作権所有